Joshua D. Schiffman,
MD
Languages Spoken: English
Labs: Website
Dr. Schiffman received his medical degree from Brown University School of Medicine, completed his Pediatric Residency, Pediatric Chief Residency, and Pediatric Hematology/Oncology Fellowship at Stanford University. He has been an investigator at the Huntsman Cancer Institute since 2008, and a faculty member at the University of Utah since 2009. Dr. Schiffman is board-certified in Pediatrics and Pediatric Hematology-Oncology.
He is currently a Professor of Pediatrics at the University of Utah, an Adjunct Professor in the Department of Oncological Sciences, and is in the Division of Hematology/Oncology at Primary Children´s Medical Center. He serves as the Medical Director of the High Risk Pediatric Cancer Clinic at Huntsman Cancer Institute where he cares for children and families with inherited risk for cancer. His specific clinical interests are cancer susceptibility in families, with a focus on the genomic changes necessary for cancer development.
Dr. Schiffman’s work in the High Risk Pediatric Cancer Clinic contributed to a landmark study in the field of clinical cancer genetics demonstrating that early cancer surveillance in families with Li-Fraumeni Syndrome significantly improves overall survival. He continues to work with children and families at high risk for cancer development to discover genes that may be targeted for both prevention and treatment of childhood cancer. Dr. Schiffman is also the Education Director for the Program in Personalized Health Care at the University of Utah, where he oversees the teaching of personalized medicine to physicians and their patients.
Clinical Locations
801-585-0100
Primary Children's Hospital
Pediatric Hematology/Oncology801-662-4700
Specialties
Board Certification and Academic Information
| Academic Departments | Pediatrics
-
Professor Oncological Sciences - Adjunct Professor |
| Academic Divisions | Pediatric Hematology/Oncology |
| Board Certification | American Board of Pediatrics (Pediatrics) American Board of Pediatrics (Sub: Pediatric Hematology-Oncology) |
| Cancer Center Programs | Nuclear Control of Cell Growth & Differentiation |
Dr. Schiffman received his medical degree from Brown University School of Medicine, completed his Pediatric Residency, Pediatric Chief Residency, and Pediatric Hematology/Oncology Fellowship at Stanford University. He has been an investigator at the Huntsman Cancer Institute since 2008, and a faculty member at the University of Utah since 2009. Dr. Schiffman is board-certified in Pediatrics and Pediatric Hematology-Oncology.
He is currently a Professor of Pediatrics at the University of Utah, an Adjunct Professor in the Department of Oncological Sciences, and is in the Division of Hematology/Oncology at Primary Children´s Medical Center. He serves as the Medical Director of the High Risk Pediatric Cancer Clinic at Huntsman Cancer Institute where he cares for children and families with inherited risk for cancer. His specific clinical interests are cancer susceptibility in families, with a focus on the genomic changes necessary for cancer development.
Dr. Schiffman’s work in the High Risk Pediatric Cancer Clinic contributed to a landmark study in the field of clinical cancer genetics demonstrating that early cancer surveillance in families with Li-Fraumeni Syndrome significantly improves overall survival. He continues to work with children and families at high risk for cancer development to discover genes that may be targeted for both prevention and treatment of childhood cancer. Dr. Schiffman is also the Education Director for the Program in Personalized Health Care at the University of Utah, where he oversees the teaching of personalized medicine to physicians and their patients.
Academic Locations
Huntsman Cancer Institute
801-587-4745
Board Certification and Academic Information
| Academic Departments | Pediatrics
-
Professor Oncological Sciences - Adjunct Professor |
| Academic Divisions | Pediatric Hematology/Oncology |
| Board Certification | American Board of Pediatrics (Pediatrics) American Board of Pediatrics (Sub: Pediatric Hematology-Oncology) |
| Cancer Center Programs | Nuclear Control of Cell Growth & Differentiation |
Research Interests
- Cancer Genetics
- Familial Cancer Susceptibility
- Li-Fraumeni Syndrome
- TP53 Mutation
- Ewing's Sarcoma
- Sarcoma
- Leukemia
- Paraganglioma
Education History
| Graduate Training | University of Utah Clinical Investigation [Genetics] M.Sc. |
| Fellowship | Stanford University Medical Center Pediatric Hematology/Oncology Fellow |
| Residency | Stanford University Medical Center Chief Medical Resident Resident |
| Residency | Stanford University Medical Center Pediatrics Resident |
| Internship | Stanford University School of Medicine Pediatrics Intern |
| Professional Medical | Brown University School of Medicine Medicine M.D. |
| Undergraduate | Brown University Psychology/Biology B.S. |
Selected Publications - Journal Articles
Journal Article
- Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, Mostyka M, Baxter-Stoltzfus A, Borczuk AC, Loda M, Cody MJ, Manne BK, Portier I, Harris ES, Petrey AC, Beswick EJ, Caulin AF, Iovino A, Abegglen LM, Weyrich AS, Rondina MT, Egeblad M, Schiffman JD, Yost CC (2020). Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 136(10), 1169-1179.
- Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, Garber JE, Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell KN, Schiffman JD, Sandoval R, Li-Fraumeni Exploration LIFE Consortium, James PA, Spurdle AB (2020). Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Hum Mutat, 41(9), 1555-1562.
- Welch BM, Allen CG, Ritchie JB, Morrison H, Hughes-Halbert C, Schiffman JD (2021). Using a Chatbot to Assess Hereditary Cancer Risk. JCO Clin Cancer Inform, 4, 787-793.
- Ritchie JB, Allen CG, Morrison H, Nichols M, Lauzon SD, Schiffman JD, Hughes Halbert C, Welch BM (2020). Utilization of health information technology among cancer genetic counselors. Mol Genet Genomic Med, 8(8), e1315.
- Boddy AM, Abegglen LM, Schiffman JD, Maley CC, Witte C (2020). Does placental invasiveness lead to higher rates of malignant transformation in mammals? Evolution, Medicine, and Public Health.
- Allen CG, Ritchie JB, Morrison H, Lauzon SD, Nichols M, Schiffman JD, Hughes Halbert C, Welch BM (2020). A thematic analysis of health information technology use among cancer genetic counselors. (Epub ahead of print) J Genet Couns.
- Donovan LN, Kohlmann W, Snow AK, Neklason DW, Schiffman JD, Maese L (2020). Germ cell mosaicism: A rare cause of Li-Fraumeni recurrence among siblings. JCO Precis Oncol, 4, 662-664.
- Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, Garber JE, Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell K, Schiffman JD, Sandoval R Li-Fraumeni Exploration LIFE Consortium, James PA, Spurdle AB (2020). Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Hum Mutat.
- Boddy AM, Abegglen LM, Pessier AP, Schiffman JD, Maley CC, Witte C (2020). Lifetime cancer prevalence and life history traits in mammals. Evolution, Medicine, and Public Health.
- Mai PL, Sand SR, Saha N, Oberti M, Dolafi T, DiGianni L, Root EJ, Kong X, Bremer RC, Santiago KM, Bojadzieva J, Barley D, Novokmet A, Ketchum KA, Nguyen N, Jacob S, Nichols KE, Kratz CP, Schiffman JD, Evans DG, Achatz MI, Strong LC, Garber JE, Ladwa SA, Malkin D, Weitzel JN (2020). Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiol Biomarkers Prev, 29(5), 927-935.
- Del Fiol G, Kohlmann W, Bradshaw RL, Weir CR, Flynn M, Hess R, Schiffman JD, Nanjo C, Kawamoto K (2021). Standards-Based Clinical Decision Support Platform to Manage Patients Who Meet Guideline-Based Criteria for Genetic Evaluation of Familial Cancer. JCO Clin Cancer Inform, 4, 1-9.
- Abbott D, OBrien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright LA (2019). Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Med, 8(18), 7924-7930.
- Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE (2019). Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. (Epub ahead of print) JAMA Oncol.
- Mowery DL, Kawamoto K, Bradshaw R, Kohlmann W, Schiffman JD, Weir C, Borbolla D, Chapman WW, Del Fiol G (2019). Determining Onset for Familial Breast and Colorectal Cancer from Family History Comments in the Electronic Health Record. AMIA Jt Summits Transl Sci Proc, 2019, 173-181.
- Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, 66(5), e27629.
- Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, Kirchhoff A, Tavtigian S, Schiffman J (2019). Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma. Int J Cancer Clin Res, 6(1).
- Dubard Gault M, Mandelker D, DeLair D, Stewart CR, Kemel Y, Sheehan MR, Siegel B, Kennedy J, Marcell V, Arnold A, Al-Ahmadie H, Modak S, Robson M, Shukla N, Roberts S, Vijai J, Topka S, Kentsis A, Cadoo K, Carlo M, Latham Schwark A, Reznik E, Dinatale R, Hechtman J, Borras Flores E, Jairam S, Yang C, Li Y, Bayraktar EC, Ceyhan-Birsoy O, Zhang L, Kohlman W, Schiffman J, Stadler Z, Birsoy K, Kung A, Offit K, Walsh MF (2018). Germline SDHA mutations in children and adults with cancer. Cold Spring Harb Mol Case Stud, 4(4).
- Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, Wistinghausen B, Termuhlen AM, Angiolillo AL, Perkins SL, Lones MA, Barnette P, Schiffman JD, Miles RR (2016). Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer, 64(7).
- Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP (2016). Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol, 35(5), 523-528.
- Aziz A, Pflieger L, OConnell N, Schiffman J, Welch BM (2017). Compatibility of Family History Cancer Guidelines With Meaningful Use Standards. JCO Clin Cancer Inform, 1.
- Welch BM, OConnell NS, Qanungo S, Halbert-Hughes C, Schiffman JD (2015). Collecting Family Health History using an Online Social Network: a Nationwide Survey among Potential Users. AMIA Annu Symp Proc, 2015, 1316-25.
- Jones KB, Schiffman JD, Kohlmann W, Randall RL, Lessnick SL, Cannon-Albright LA (2011). Complex genotype sarcomas display familial inheritance independent of known cancer predisposition syndromes. Cancer Epidemiol Biomarkers Prev, 20(5), 751-7.
- Meeker ND, Yang JJ, Schiffman JD (2010). Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin Pharmacother, 11(10), 1621-32.
The Scope & Other Podcasts
- Health Care Insider: The Ethics of Genetic Screenings
- Obtaining An Accurate Family Health History is Crucial
- What Elephants Can Teach Us About Evading Cancer
- An Initiative to Prevent Childhood Cancer Before it Starts
- Knowing the Difference Between Inherited and Acquired Cancers Can Save Lives
- Genomics: The Key to Understanding Rare Cancers -- Joshua Schiffman, MD
- Joshua Schiffman, MD - Newfound Hope for Families of Kids with Cancer
- Getting to Know Joshua Schiffman, MD